Supplements for Longevity and Cognition: Ranked by Evidence

Supplements for Longevity and Cognition: Ranked by Evidence

Supplements can matter after 40, but they are rarely the first-order answer. The highest-confidence stack is still aerobic fitness, muscle preservation, sleep, blood-pressure control, metabolic health, and recovery. This guide ranks the supplement categories on Timeless Wisdom by evidence so readers can see what deserves serious attention, what belongs in the “interesting but uncertain” bucket, and what should stay out of a default stack.

How to use this guide

  • Best evidence: Omega-3 for selected cardiometabolic use cases, CoQ10 in some cardiovascular contexts, and berberine when glucose or lipid management is the real problem.
  • Best for: Adults 40+ who want a supplement map ranked by certainty rather than by novelty.
  • Highest uncertainty: NMN / NAD+ boosters for healthy aging, ergothioneine as a longevity default, and specialty nootropics such as huperzine A or racetams for healthy adults.

Supplements ranked by evidence, not by internet buzz

Supplement Evidence level Key quantitative finding Best for Main risk or limitation
Omega-3 Moderate 8% lower CHD mortality (RR 0.92, 95% CI 0.86-0.98) across 13 RCTs and 127,477 participants (Hu et al., 2019) Triglycerides, cardiometabolic support Cognition and direct longevity claims remain softer than the marketing
Berberine Moderate FBG -0.72 mmol/L, HbA1c -0.65% in 28 RCTs of T2D patients (Asbaghi et al., 2022) Glucose control, insulin-resistance contexts GI side effects, drug interactions, weak logic without metabolic indication
CoQ10 Moderate 43% reduction in major adverse cardiac events in chronic heart failure, Q-SYMBIO trial, n=420 (Mortensen et al., 2014) Selected cardiovascular settings and statin-related use cases General healthy-aging use much less established than heart-related contexts
Taurine Emerging Blood pressure reduction: SBP -3.1 mmHg, DBP -1.9 mmHg in meta-analysis of RCTs (Wang et al., 2024) Cardiometabolic markers, selected recovery Long-term healthy-aging benefit still unproven
NMN / NAD+ boosters Emerging FBG -3.38 mg/dL, HOMA-IR -0.80 in meta-analysis of RCTs (Zhong et al., 2024) Biomarker-focused experimentation Small trials (n=30-80), no hard clinical endpoints, cost $40-150/month
Ergothioneine Emerging Pilot study in MCI subjects showed potential cognitive benefit but small sample (Cheah et al., 2024) Mechanistically interesting antioxidant Human intervention evidence still too thin for routine use
Resveratrol Speculative Inconsistent results across human trials; bioavailability remains a fundamental limitation Mechanism-driven interest only Translation from theory to useful human results has remained underwhelming
Huperzine A, racetams Speculative Condition-specific data only (e.g., huperzine A in Alzheimer’s disease, not healthy aging) Niche, case-specific Regulatory ambiguity, high risk of overstated claims

What belongs in the top tier

The highest-confidence supplement lane is narrower than most longevity blogs admit. Omega-3 belongs here when the use case is cardiometabolic support: Hu et al. (2019) analyzed 13 RCTs with 127,477 participants and found an 8% reduction in coronary heart disease mortality (RR 0.92; 95% CI 0.86-0.98) and a 5% reduction in total CHD events with marine omega-3 supplementation (PMID: 30971107). Berberine belongs here when someone actually has glucose or insulin-resistance issues: meta-analytic data across 28-46 RCTs show fasting glucose reductions of 0.67-0.72 mmol/L and HbA1c reductions of 0.55-0.65% (Asbaghi et al., 2022; Guo et al., 2021). CoQ10 belongs here mainly in cardiovascular contexts: the Q-SYMBIO trial showed a 43% reduction in major adverse cardiac events over 2 years in 420 patients with chronic heart failure (Mortensen et al., 2014; PMID: 25282031). None of these compounds outrank training, sleep, or metabolic basics, but at least they have a real clinical lane.

What belongs in the middle tier

Taurine, NMN, broader NAD+ boosters, and ergothioneine are better viewed as monitored experiments than as default recommendations. NMN meta-analyses show statistically significant improvements in fasting glucose and insulin resistance (Zhong et al., 2024) as well as grip strength and walking speed in older adults (Zhang et al., 2024), but these come from trials with 30-80 participants and 8-12 weeks of follow-up. Taurine supplementation reduced systolic blood pressure by 3.1 mmHg and diastolic by 1.9 mmHg in a meta-analysis of RCTs (Wang et al., 2024). The biology is interesting. Some human data exist. But the jump from biomarker changes or small trials to reliable long-term benefit is still too large for certainty.

What belongs in the speculative tier

Resveratrol and specialty nootropics such as huperzine A or racetams attract a lot of attention because the mechanisms sound impressive. That is exactly why they need the highest bar. A mechanism is not a clinical outcome, and disease-specific or poorly standardized evidence should not be generalized into a healthy-adult longevity stack.

How to decide whether a supplement has earned a place in your stack

  • Start with the use case. If you cannot name the real problem you are trying to solve, the supplement has not earned a place yet.
  • Check the evidence type. Human randomized trials and systematic reviews deserve more weight than mechanistic enthusiasm.
  • Surface the downside. Interactions, cost, product quality, and monitoring burden belong in the decision.
  • Compare it with the basics. If sleep, training, blood pressure, protein intake, or waistline control are weak, fix those before adding a speculative compound. For reference: 30-60 min/week of strength training is associated with 10-17% lower mortality (Momma et al., 2022), and high cardiorespiratory fitness with 80% lower mortality versus low fitness (Mandsager et al., 2018).

What is the best-supported supplement category after 40?

There is no universal winner, but omega-3 (8% CHD mortality reduction in 127,477 participants), berberine in the right metabolic context (FBG -0.72 mmol/L in T2D), and CoQ10 in selected cardiovascular settings (43% fewer MACE in heart failure) currently have the clearest practical lanes.

Are NMN and NAD+ boosters proven longevity supplements?

No. They have genuine biological interest and early human data from trials of 30-80 participants, but they have not earned the label of proven longevity interventions in healthy adults. No NMN trial has measured mortality or disease incidence.

Should a rational supplement stack come before training, sleep, and metabolic health?

No. Supplements should support a high-functioning base, not replace it. The evidence gap between foundational interventions (n=100,000+, mortality endpoints) and even the best supplement data (n=30-420, surrogate markers) is very large.

Key evidence sources

Related guides

Next step: Use the broader longevity decision map to decide whether you even need a supplement intervention, then go deeper on the one or two compounds that match a real use case instead of building a novelty stack.

Free guide

The Evidence-Backed Longevity Stack for Adults 40+

Get the practical stack guide and join the evidence-digest request list for adults 40+ focused on longevity, cognition, recovery, and performance.

Get the free guideOne focused guide. No hype stack.